Project Grant HT9425261E281
Award Date 6/15/26
Completion Date 6/14/29
Dollars Obligated $1.3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
- Federal Grant Award Summary New York University School of Medicine received a $750,962 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on June 15, 2026, with an ultimate completion date of June 14, 2029. The award supports research investigating neoadjuvant checkpoint and interleukin-6 (IL-6) blockade therapies, with a focus on elucidating the mechanisms underlying therapeutic benefits and associated toxicities....
- Federal Grant Award Summary New York University School of Medicine received a $833,334 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), awarded on September 30, 2026, with performance through September 29, 2029. The award supports research to identify pathways that prevent the emergence of drug-tolerant persisters—a critical area of biomedical investigation relevant to treatment resistance and therapeutic development. This...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded Sloan-Kettering Institute For Cancer Research a $533,308 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2029. The award funds research titled "Integrated Immunomodulatory Analysis of LAG3 Inhibition in Renal Cell Carcinoma," which investigates lymphocyte-activation gene 3 (LAG3) checkpoint inhibition as a therapeutic...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $352,000 under the Military Medical Research and Development program (CFDA 12.420) to the Sloan-Kettering Institute for Cancer Research for the project period September 1, 2025, through August 31, 2027. The award supports research focused on augmenting the in vivo efficacy of a novel lanosterol synthase inhibitor in glioblastoma treatment. This research aligns with the DHA's mission to transform healthcare for service...
- Federal Grant Award Summary New York University School of Medicine received a $2.01M Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2025, through June 30, 2028. The award supports research titled "Targeting RAGE After Particulate Matter Exposure: Metabolic Dysregulation and Disease Mitigation," conducted at NYU's location in New York, New York. This research investigates the...
- Federal Project Grant Award Summary New York University received a $791,063 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded on September 30, 2025, with completion targeted for September 29, 2029. The award supports the implementation of a formal postvention program designed to serve military mental health clinicians. Postvention programs typically provide crisis intervention, support services, and recovery...
- Federal Grant Award Summary New York University School of Medicine has received a $680,757 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research titled "Targeting RAGE After Particulate Matter Exposure: Metabolic Dysregulation and Disease Mitigation." The three-year award, effective July 1, 2025 through June 30, 2028, supports biomedical research investigating the mechanisms by which particulate matter...
- Summary New York University School of Medicine received a $1.67 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded September 30, 2026, with a completion date of September 29, 2029. The award supports research to identify pathways that prevent the emergence of drug-tolerant persisters—a critical objective within the DHA's broader portfolio of biomedical research initiatives designed to transform healthcare...
- Federal Project Grant Award Summary The Sloan-Kettering Institute for Cancer Research received a $176,000 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective November 1, 2025, through October 31, 2027. The award funds research exploring a novel antibody-drug conjugate (ADC) strategy designed to block MYC protein production in neuroblastoma (NB), a pediatric cancer of the nervous system. This research...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded Icahn School of Medicine at Mount Sinai a $507,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2027. The award supports research to investigate tumor-intrinsic epigenetic mechanisms that modulate antitumor immune responses in metastatic prostate cancer. This research initiative advances the DHA's mission to transform healthcare...